Literature DB >> 10217337

Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study.

T W May1, B Rambeck, U Jürgens.   

Abstract

The aim of this retrospective study was to investigate the influence of oxcarbazepine (OCBZ) and methsuximide (MSM) on lamotrigine (LTG) serum concentrations. The effect of OCBZ compared to carbamazepine (CBZ) and the effect of MSM on LTG serum concentrations were examined in patients with and without valproic acid (VPA) comedication. Altogether, 376 samples from 222 patients were analyzed in routine drug monitoring. Two or more serum samples from the same patient were considered only if the comedication had been changed. For statistical evaluation, regression analytical methods and an analysis of variance were performed. For the analysis of variance, the LTG serum concentration in relation to LTG dose/ body weight--level-to-dose ratio (LDR), in (microg/mL)/(mg/kg)--was calculated and compared for different drug combinations. The nonlinear regression analysis including the LTG dose per body weight, age, gender, and the different kinds of comedication revealed that these variables have a significant influence on LTG serum concentration (r2 = 0.724). The relationship between LTG dose/body weight and serum concentration deviates only slightly from linearity, the LTG concentration was about 18% lower in women than in men, and age had a significant influence. The data indicate that children have significantly lower LTG concentrations than adults on a comparable LTG dose per body weight and that children may be more prone to enzyme induction by comedicated drugs. Methsuximide has a strong inducing effect on the LTG metabolism and decreases the LTG concentrations markedly (about 70% compared to LTG monotherapy). Carbamazepine also reduces the LTG concentrations considerably (by 54%). The inducing effect of OCBZ (29%) was less pronounced but also significant. The inducing effect of MSM, CBZ, and OCBZ was also seen in combination with VPA: VPA alone increases the LTG concentration approximately 211%, whereas in addition to MSM (8%), CBZ (21%), or OCBZ (111%), the increase of LTG was significantly smaller. The analysis of variance confirmed the results of the regression analysis. The effect of MSM on the LTG concentration should be considered if MSM is added or withdrawn in patients treated with LTG. Oxcarbazepine had a less pronounced inducing effect on LTG metabolism compared to CBZ. If CBZ is replaced by OCBZ as comedication, an increase in LTG serum concentrations should be expected.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10217337     DOI: 10.1097/00007691-199904000-00007

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  23 in total

1.  Increase in dihydroxycarbamazepine serum levels in patients co-medicated with oxcarbazepine and lamotrigine.

Authors:  N Guénault; P Odou; H Robert
Journal:  Eur J Clin Pharmacol       Date:  2003-10-24       Impact factor: 2.953

Review 2.  [Therapeutic drug monitoring in epileptology and psychiatry].

Authors:  C Brandt; P Baumann; G Eckermann; C Hiemke; T W May; B Rambeck; B Pohlmann-Eden
Journal:  Nervenarzt       Date:  2008-02       Impact factor: 1.214

3.  Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy.

Authors:  Iva Klarica Domjanović; Mila Lovrić; Vladimir Trkulja; Željka Petelin-Gadže; Lana Ganoci; Ivana Čajić; Nada Božina
Journal:  Br J Clin Pharmacol       Date:  2018-07-08       Impact factor: 4.335

Review 4.  Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferase induction.

Authors:  M Strolin Benedetti; R Whomsley; E Baltes; F Tonner
Journal:  Eur J Clin Pharmacol       Date:  2005-11-24       Impact factor: 2.953

Review 5.  Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?

Authors:  Svein I Johannessen; Torbjörn Tomson
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 6.  Oxcarbazepine: an update of its efficacy in the management of epilepsy.

Authors:  K Wellington; K L Goa
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 7.  Treating epilepsy in the elderly: safety considerations.

Authors:  S Arroyo; G Kramer
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

8.  Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.

Authors:  Wei-Wei Lin; Xi-Wen Li; Zheng Jiao; Jin Zhang; Xin Rao; Da-Yong Zeng; Xin-Hua Lin; Chang-Lian Wang
Journal:  Eur J Clin Pharmacol       Date:  2018-11-19       Impact factor: 2.953

Review 9.  Oxcarbazepine: a review of its use in children with epilepsy.

Authors:  Lynne Bang; Karen Goa
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

10.  [How is oxcarbazepine different from carbamazpine?].

Authors:  D Schmidt; C E Elger
Journal:  Nervenarzt       Date:  2004-02       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.